Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesProvectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0475 USD -0.00 ( 8.65%)
Last update at 2026-11-06T15:32:00Z
VOLUME
2010
Market Cap
41.07M

Momentum Score

…

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.05
Low
0.05
High
52 Week Price Range
0.06
Low
0.17
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Provectus Biopharmaceuticals is a clinical-stage company developing an intratumoral immunotherapy based on rose bengal for treatment of solid tumors. Long-term growth drivers include positive clinical data, regulatory approvals, licensing or commercialization partnerships and expansion into additional oncology indications. The therapy may benefit patients by causing local tumor ablation with potential systemic immune responses, and investors may find exposure to a differentiated, development-stage oncology asset attractive.
Primary risks are clinical or regulatory setbacks, persistent need for external financing, lack of commercial revenue and low trading liquidity of its OTCQB listing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
7.77%
Revenue TTM
0.60M
Revenue Per Share
0.00
Gross Profit TTM
-1.32M
Debt / Equity
-
ROE
-
Net Debt
2.05M
ROCE
55.09%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -3.55M -5.54M -6.68M -7.73M -9.00M
Net income -3.55M -5.54M -6.68M -6.92M -8.15M
Selling general administrative 2.02M 2.05M 2.15M 2.30M 3.31M
Gross profit - - - - 0.00M
Reconciled depreciation 0.01M 0.01M 0.24M 0.69M 0.69M
Ebit -3.39M -4.64M -4.93M -6.28M -8.03M
Ebitda -3.38M -4.56M -4.69M -4.78M -6.50M
Non operating income net other - - 0.03M 0.02M 0.02M
Operating income -3.39M -4.64M -4.96M -6.30M -8.05M
Interest expense 0.16M 0.96M 1.75M 1.46M 0.97M
Interest income - 0.00M 0.00M 0.02M 0.02M
Net interest income -0.16M -0.96M -1.74M -1.46M -0.97M
Non recurring - - - -0.68M -0.82M
Income tax expense - - - - 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 3.39M 4.64M 4.96M -6.30M 7.23M
Cost of revenue - - - - 0.00M
Total other income expense net 0.00M 0.06M -0.00M 0.70M 0.84M
Net income from continuing ops -3.55M -5.54M -6.68M -7.73M -9.00M
Net income applicable to common shares -3.55M -5.54M -6.68M -6.92M -8.15M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 2.04M 3.51M 0.59M 1.48M 1.99M
Intangible assets - - - 0.23M 0.90M
Other current assets 1.41M 2.42M 0.32M 0.35M 0.37M
Total liab 8.27M 7.70M 30.80M 25.55M 19.41M
Total stockholder equity -6.23M -4.19M -30.21M -24.07M -17.42M
Other current liab 1.51M 2.65M 2.09M 0.08M -
Common stock 0.42M 0.42M 0.40M 0.39M 0.38M
Capital stock 0.44M 0.44M 0.40M 0.39M 0.38M
Retained earnings -249.59M -246.03M -240.49M -233.82M -226.89M
Other liab - - - 2.73M -
Cash 0.02M 0.68M 0.10M 0.59M 0.05M
Total current liabilities 8.19M 7.70M 30.71M 3.02M 4.10M
Net debt 2.05M 1.02M 23.57M 19.58M 13.88M
Short term debt - - 16.62M 0.50M -
Short long term debt 2.07M 1.70M 23.63M 0.50M -
Other stockholder equity -0.04M -0.03M -0.03M -0.02M -
Property plant equipment 0.14M 0.07M 0.04M 0.06M 0.07M
Total current assets 1.90M 3.44M 0.42M 1.00M 1.02M
Net tangible assets -6.25M -4.21M -30.21M -24.30M -18.32M
Net receivables 0.00M 0.01M 0.00M 0.06M 0.60M
Long term debt - - 0.04M 13.00M 13.93M
Accounts payable 2.09M 1.29M 12.00M 2.45M 4.10M
Common stock total equity - - 0.40M 0.39M 0.38M
Retained earnings total equity - - -240.49M -233.82M -226.89M
Non currrent assets other - - 0.12M 0.19M 0.97M
Non current assets total 0.14M 0.07M 0.17M 0.48M 0.97M
Capital lease obligations 0.12M 0.05M 0.13M 0.21M -
Long term debt total - - - 13.00M 13.93M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - - 0.00M
Change to liabilities -0.18M 2.83M 1.82M -0.07M 0.65M
Net borrowings 1.37M 2.91M 3.08M 6.43M 2.61M
Total cash from financing activities 1.37M 4.02M 3.60M 6.75M 5.15M
Change to operating activities 0.63M 1.64M 2.31M 2.14M 2.14M
Net income -3.55M -5.54M -6.68M -6.92M -8.15M
Change in cash -1.68M 3.01M -0.49M 0.56M -0.05M
Begin period cash flow 3.11M 0.10M 0.59M 0.05M 0.11M
End period cash flow 1.43M 3.11M 0.10M 0.59M 0.05M
Total cash from operating activities -3.04M -1.01M -4.09M -6.19M -5.20M
Issuance of capital stock 0.00M 0.15M - - -
Depreciation 0.01M 0.01M 0.24M 0.69M 0.69M
Sale purchase of stock - - 0.42M 0.27M 0.67M
Other cashflows from financing activities - 0.15M 0.10M 0.05M 1.87M
Change to netincome 0.06M 0.04M 0.13M 0.02M 0.08M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change receivables - - 0.05M 0.00M 1.50M
Cash flows other operating - - 0.34M 0.09M 0.03M
Cash and cash equivalents changes - - -0.49M 0.56M -0.05M
Change in working capital 0.45M 4.47M 2.14M -0.05M 2.18M
Stock based compensation 0.00M 0.02M 0.13M 0.02M -
Other non cash items 0.05M 0.08M 0.07M 0.07M 0.08M
Free cash flow -3.04M -1.01M -4.09M -6.19M -5.20M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PVCT
Provectus Biopharmaceuticals Inc		 -0.00
8.65%		 0.05 - - 67.35 5.44 151.25 -15.14
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

10025 Investment Drive, Knoxville, TN, United States, 37932

866 594 5999

https://www.provectusbio.com

4

Name Title Year Born
Dr. Eric A. Wachter Co-Founder & CTO 1963
Ms. Heather Raines CPA Chief Financial Officer 1967
Mr. Bruce Horowitz COO & Director 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…